

Mapping of innovative medicines

EFCCA has undertaken an **exhaustive mapping of all innovative medicines** and devices that are available in member countries of EFCCA.

31 countries (32 patient associations) **from the EFCCA network** participated between October 2016 and December 2017.

The results show existing health inequalities between member countries and regions on issues such as healthcare systems, reimbursement policies and access to treatment.



Reimbursement policies



Regional differences



Access to innovative medicines



Patients' choice of doctor




EFCCA

European Federation of Crohn's &
Ulcerative Colitis Associations



Reimbursement policies

Having to pay everything up front, even with a later full reimbursement, can be difficult for those with low income and can even lead to the patient not being able to purchase prescription medicines.




Regional differences in some countries

- the country's federations making up their own laws or having their own insurance systems
- geographical reasons
- distribution of specialists

Such variations can put IBD patients in very unequal positions in terms of access to care, even if they live in the same country and within the same health care system.



Availability and access to innovative medicines



- Participants were asked about access to seven medicines (5 biologics and 2 biosimilars)
- only 1 (Humira) of the 7 medicines was approved for IBD patients in all participating countries
 - only five countries could offer access to all of the 7 medicines to IBD patients



Patients' choice of doctor

A good patient-physician relationship is associated with better compliance to treatment. Being able to choose one's health care provider, instead of being appointed to one, may help develop a patient-physician relationship that promotes the patient's compliance to treatment and quality of life.



Recommendations



Access to new innovative therapies needs to be accelerated; national associations are encouraged to take advantages of the outcomes of this project in their work.



In rural areas and regions where distances are long, the possibilities of telemedicine and online services should be developed.



Developing **IBD patient registries** on national or European level **needs to be encouraged.**

About EFCCA

European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) is an umbrella organization representing 34 national IBD patient associations. **EFCCA aims to improve the quality of life for people with IBD** and give them a louder voice and higher visibility across Europe and beyond. For more information, visit www.efcca.org

Sponsors

This project received an unrestricted multi-stakeholder grant by Celltrion, Pfizer, Takeda and Otsuka



EFCCA
European Federation of Crohn's &
Ulcerative Colitis Associations

Rue des Chartreux 33-35, B-1000 Brussels
Tel/Fax: +32 2 540 8434
<http://www.efcca.org>
E-mail: bella.haaf@efcca.org